Quantcast

Latest hemophilia Stories

2014-09-18 08:30:32

An Educational Program Based on the Findings From the Hemophilia Experiences, Results, and Opportunities (HERO) Study Launched at NHF's 66th Annual Meeting NEW YORK and PLAINSBORO, N.J., Sept. 18, 2014 /PRNewswire/ -- Novo Nordisk announced today its support of the National Hemophilia Foundation's (NHF) new three-year initiative, Collaborating in Care, which provides support to people with hemophilia and their families/caregivers to help address the physical and psychosocial...

2014-09-04 23:07:35

National Hemophilia Foundation Encourages Patient Community to Take an Active Part in Strategies, Policies, and Programs Directly Affecting Their Lives at 66th Annual Meeting in Washington, DC New York, NY (PRWEB) September 04, 2014 The largest annual gathering of the bleeding disorders community in the United States will take place at the 66th Annual Meeting of the National Hemophilia Foundation (NHF) from Thursday, September 18th to Saturday, September 20th at the Washington Marriott...

2014-08-26 08:30:42

- Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Regimens of Either Every Three to Five Days or Once-Weekly Infusions - MISSISSAUGA, ON, Aug. 26, 2014 /CNW/ - Today Biogen Idec (NASDAQ: BIIB) announces that Health Canada has approved ELOCTATE(TM) [Antihemophilic Factor (Recombinant BDD), Fc Fusion Protein] for the control and prevention of bleeding episodes and routine prophylaxis in adults and children aged 12 and older with hemophilia A.(1) ELOCTATE is...

2014-08-25 08:28:41

PLAINSBORO, N.J., Aug. 25, 2014 /PRNewswire/ -- Novo Nordisk announced the launch of the HeroPath(TM) Life Coach Program, an empowering, yearlong program that connects teens and young adults with life coach and peer support. Novo Nordisk has partnered with Jeffrey Leiken, creator of HeroPath(TM) and Master Trainer at Evolution Mentoring, to offer this program to young people with hemophilia A or B with or without inhibitors. The program kicked off last weekend and will continue with...

2014-08-21 16:24:44

Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand DEERFIELD, Ill., Aug. 21, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) reports Baxter International Inc. today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary...

2014-06-26 23:09:03

The National Hemophilia Foundation (NHF) with the guidance of its Medical and Scientific Advisory Council (MASAC), today announced that it is initiating a multi-year project to develop evidence-based clinical practice guidelines (CPGs) to ensure that patients with hemophilia in the United States and elsewhere receive high quality care. New York, NY (PRWEB) June 26, 2014 The National Hemophilia Foundation(NHF) with the guidance of its Medical and Scientific Advisory Council (MASAC), today...

2014-05-16 16:24:47

Five U.S. Researchers among Recipients of Prestigious Award WHIPPANY, N.J., May 16, 2014 /PRNewswire/ -- Bayer HealthCare announced today the 2014 recipients of the Bayer Hemophilia Awards Program (BHAP), a unique initiative dedicated to supporting innovative research and educational initiatives that benefit people with hemophilia around the world. American researchers and clinicians represented the largest group of winners from one country, with five individuals receiving awards. This year,...

2014-05-11 20:21:16

Data showing improved pharmacokinetic profile to be presented at World Federation of Hemophilia Congress MELBOURNE, Australia, May 11, 2014 /PRNewswire/ -- Interim Phase II/III and III findings presented today by CSL Behring at the World Federation of Hemophilia (WFH) 2014 Congress demonstrate an improved pharmacokinetic (PK) profile of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) among hemophilia B patients of all age groups. These...

2014-05-09 12:25:57

-- Leading-edge science at the core of $250 million expansion to drive long-term growth in promising bleeding disorders portfolio KING OF PRUSSIA, Pa., May 9, 2014 /PRNewswire/ -- CSL Limited (ASX:CSL), parent company of CSL Behring which is based in King of Prussia, PA, today opened the CSL Behring Biotechnology Manufacturing Facility in Melbourne, Australia. The new facility, located adjacent to the site's manufacturing plant for plasma products, is the centerpiece of CSL's...

2014-04-17 08:28:45

- Three-year commitment of up to 20 million units per year of blood clotting medicines to treat hemophilia patients in developing countries BARCELONA, Spain, April 17, 2014 /PRNewswire/ -- Grifols, S.A. (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) today announced that it will donate up to 20 million units of coagulation therapies in each of the next three (3) years to the World Federation of Hemophilia (WFH). Grifols has been a proud supporter of the WFH and its noble efforts for nearly a...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'